Karaseva, Nina

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,309

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Mansfield, A. S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., et al. (2020) · Annals of Oncology

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 193